Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia

Psychiatric Services

Volumn 64, Issue 6, 2013, Pages 527-533

  Gören, Jessica L ^a,b   Meterko, Mark ^b   Williams, Sandra ^b   Young, Gary J ^b,c   Baker, Errol ^b   Chou, Chia Hung ^d   Kilbourne, Amy M ^e   Bauer, Mark S ^b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

^d NORTHEASTERN UNIVERSITY   (United States)

^e Center for Clinical Management Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG UTILIZATION; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL GEOGRAPHY; MEDICAL HISTORY; MENTAL PATIENT; MONOTHERAPY; PATIENT CARE; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; VETERAN; VETERANS HEALTH;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84883183997     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.002022012     Document Type: Article

References (35)

1. Dencker SJ: The need for long-term neuroleptic treatment in schizophrenia. Acta Psychiatrica Scandinavica Supplementum 291:29-43, 1981
2. Jäger M, Riedel M, Obermeier M, et al: Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patients. Schizophrenia Research 118:183-188, 2010
3. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353: 1209-1223, 2005
4. McIlwain ME, Harrison J, Wheeler AJ, et al: Pharmacotherapy for treatmentresistant schizophrenia. Journal of Neuropsychiatric Disease and Treatment 7: 135-149, 2011
5. Conley RR, Kelly DL: Management of treatment resistance in schizophrenia. Biological Psychiatry 50:898-911, 2001
6. American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia, 2nd ed. American Journal of Psychiatry 161(Feb suppl):1-56, 2004
7. National Institute of Health and Clinical Excellence: Core interventions in the treatment and management of schizophrenia in primary and secondary care (CG82). March 2009. Available at guidance.nice.org.uk/CG82. Accessed Dec 3, 2011
8. Kreyenbuhl J, Buchanan RW, Dickerson FB, et al: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophrenia Bulletin 36:94-103, 2010
9. Behavioral Healthcare Performance Measurement System Measures. Alexandria, Va, National Association of State Mental Health Program Directors Research Institute, March 2007. Available at www.nri-inc.org. Accessed Dec 3, 2011
10. Moore TA, Buchanan RW, Buckley PF, et al: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. Journal of Clinical Psychiatry 68:983-990, 2007
11. Kreyenbuhl J, Valenstein M, McCarthy JF, et al: Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophrenia Research 84:90-99, 2006
12. Sernyak MJ, Rosenheck RA: Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Psychiatric Services 59: 567-569, 2008
13. Grohmann R, Engel RR, Geissler KH, et al: Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 37(suppl 1):S27-S38, 2004
14. Centorrino F, Goren JL, Hennen J, et al: Multiple versus single antipsychotic agents for hospitalized psychiatric patients: casecontrol study of risks versus benefits. American Journal of Psychiatry 161: 700-706, 2004
15. Conley RR, Kelly DL, Lambert TJ, et al: Comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatric Services 56:320-323, 2005
16. Fayek M, Flowers C, Signorelli D, et al: Psychopharmacology: underuse of evidencebased treatments in psychiatry. Psychiatric Services 54:1453-1454, 1456, 2003
17. Taylor DM, Young C, Paton C: Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. Journal of Clinical Psychiatry 64:30-34, 2003
18. Wheeler AJ: Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Annals of Pharmacotherapy 42:852-860, 2008
19. Schumacher JE, Makela EH, Griffin HR: Multiple antipsychotic medication prescribing patterns. Annals of Pharmacotherapy 37:951-955, 2003
20. VA National Psychosis Registry. Ann Arbor, Mich, US Department of Veterans Affairs, 2009
21. Bronskill SE, Gill SS, Paterson JM, et al: Exploring variation in rates of polypharmacy across long-term care homes. Journal of the American Medical Directors Association (Epub ahead of print, Aug 12, 2011)
22. Weissman EM: Antipsychotic prescribing practices in the Veterans Healthcare Administration -New York metropolitan region. Schizophrenia Bulletin 28:31-42, 2002
23. Harrison J, Janlöv M, Wheeler AJ: Patterns of clozapine prescribing in a mental health service in New Zealand. Pharmacy World and Science 32:503-511, 2010
24. Lee B, Walker V: Polypharmacy as the initial second-generation antipsychotic treatment. Psychiatric Services 59:717, 2008
25. Tsutsumi C, Uchida H, Suzuki T, et al: The evolution of antipsychotic switch and polypharmacy in natural practice -a longitudinal perspective. Schizophrenia Research 130:40-46, 2011
26. McCarthy JF, Blow FC, Valenstein M, et al: Veterans Affairs Health System and mental health treatment retention among patients with serious mental illness: evaluating accessibility and availability barriers. Health Services Research 42:1042-1060, 2007
27. Kreyenbuhl JA, Valenstein M, McCarthy JF, et al: Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatric Services 58:489-495, 2007
28. Ren XS, Kazis LE, Lee AF, et al: Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. Journal of Clinical Pharmacy and Therapeutics 27:441-451, 2002
29. Gilmer TP, Dolder CR, Folsom DP, et al: Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatric Services 59:1007-1010, 2007
30. Sernyak MJ, Rosenheck R: Clinicians' reasons for antipsychotic coprescribing. Journal of Clinical Psychiatry 65:1597-1600, 2004
31. Kilbourne AM, Greenwald DE, Hermann RC, et al: Financial incentives and accountability for integrated medical care in Department of Veterans Affairs mental health programs. Psychiatric Services 61: 38-44, 2010
32. Santone G, Bellantuono C, Rucci P, et al: Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy. Pharmacoepidemiology and Drug Safety 20:441-449, 2011
33. Kilbourne AM, Pincus HA, Schutte K, et al: Management of mental disorders in VA primary care practices. Administration and Policy in Mental Health 33:208-214, 2006
34. Daumit GL, Crum RM, Guallar E, et al: Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Archives of General Psychiatry 60:121-128, 2003
35. Correll CU, Frederickson AM, Kane JM, et al: Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophrenia Research 89:91-100, 2007